Wegovy medication doses: what the schedule actually means for you

The myth: a lower dose means weaker treatment

The most common misunderstanding about Wegovy is that the earlier doses are doing very little. People start on 0.25 mg, feel impatient, and wonder whether they have been given a "trial" version. They have not. The early steps exist because semaglutide slows gastric emptying and acts on appetite centres in the brain; introduce it too fast and nausea, vomiting and fatigue can be severe enough to make people stop altogether. The 0.25 mg starting dose is calibrated to let your body adjust, not to produce weight loss. It does its job well, which is why the schedule was designed around it.

The STEP 1 trial, published in the New England Journal of Medicine, found that participants reached an average weight reduction of around 15% over 68 weeks on the 2.4 mg maintenance dose. That result came from following the full titration schedule, not from jumping ahead of it. Rushing the ladder is the single most likely way to derail it.

There is also a practical storage detail worth knowing early: Wegovy pens are refrigerated (2–8°C), so many people keep the current pen in the fridge door alongside everyday items, easy to spot, hard to forget. The Patient Information Leaflet covers the exact room-temperature window for short periods away from the fridge; always check that rather than guessing.

The full Wegovy dose schedule in plain terms

If you want to understand how Wegovy doses are structured from the initial 0.25 mg step through to the 2.4 mg maintenance level, the standard UK titration pathway runs as described in the NHS semaglutide medicines guide: 0.25 mg for approximately four weeks, then 0.5 mg, then 1.0 mg, then 1.7 mg, arriving finally at the 2.4 mg maintenance dose. Each step is roughly one month. That places most people at maintenance somewhere between months four and five, assuming no reason to pause.

The titration process is not automatic. Your prescriber reviews your progress before confirming a dose increase, tolerability, weight response and any new health information all factor in. Some people hold at an intermediate dose for longer; some find 1.7 mg is their practical ceiling and stay there. Neither of those is a failure. The right maintenance dose is the highest dose you tolerate well, which is a clinical judgement, not a target you set yourself.

If you want a closer look at the physical pen formats and how the pre-set injection volumes correspond to each step, the Wegovy pen doses page explains that in detail, including what the dose window on the pen tells you before you inject.

The 7.2 mg dose: what changed in 2026 and who it applies to

In January 2026 the MHRA approved a 7.2 mg maintenance dose for Wegovy, and on 14 April 2026 approved a dedicated single-dose 7.2 mg pen, a pre-set auto-injector with a covered needle that locks after use. This approval applies to adults with a BMI of 30 or above only; it is not licensed for the cardiovascular indication or for lower BMI thresholds. The starting dose remains 0.25 mg regardless of which maintenance target is ultimately reached, and the titration steps between remain the same. You cannot begin at 7.2 mg. The MHRA's announcement confirms the pen's approval and the patient criteria.

Clinical trial data for 7.2 mg reported average weight reduction of around 20.7% over 72 weeks, a figure that narrows the gap with tirzepatide 15 mg results considerably. Whether 7.2 mg is the right target for a given patient is a conversation for a prescriber: not every patient needs or tolerates the highest dose, and the evidence base for 7.2 mg is newer than for 2.4 mg. For context on how Wegovy's results sit alongside other licensed options, the Wegovy overview covers the comparative picture.

Doses, eligibility and the private route

Wegovy is a prescription-only medicine. On the NHS, access follows the NICE TA875 criteria: adults with a BMI of 35 or above (or 30–34.9 in certain circumstances) plus at least one weight-related condition, used within a specialist weight management service for a maximum of two years. Waiting lists can be long, and the criteria are specific. For people who do not meet NHS thresholds or who prefer not to wait, a private prescription through a regulated UK pharmacy is the legal alternative, provided a qualified prescriber has assessed your suitability first.

Lower BMI thresholds apply for some ethnic backgrounds under UK guidance, which your prescriber will account for at assessment. The weight-loss treatment overview sets out the licensed options side by side. If cost is a factor in your thinking, the Wegovy pricing page explains what a legitimate private prescription genuinely includes and what to watch for when comparing providers. If you are planning a holiday and wondering whether it is safe to skip a week of Wegovy while you are away, doses and suitability are confirmed at consultation, our prescribers at nume review every case individually, the same day.

If you are ready to find out whether Wegovy is clinically appropriate for you, start your free consultation and a GPhC-registered Independent Prescriber will review your information the same day.